{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:31:39Z","timestamp":1790015499069,"version":"4.0.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007928","name":"Ningbo Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["No. 2022J053"],"award-info":[{"award-number":["No. 2022J053"]}],"id":[{"id":"10.13039\/501100007928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007928","name":"Ningbo Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["No.2023J204"],"award-info":[{"award-number":["No.2023J204"]}],"id":[{"id":"10.13039\/501100007928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple myeloma (MM) is a severely debilitating and fatal B-cell neoplastic disease. The discovery of disease-associated proteins with causal genetic evidence offers a chance to uncover novel therapeutic targets.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>First, we comprehensively investigated the causal association between 2994 proteins and MM through two-sample mendelian randomization (MR) analysis using summary-level data from public genome-wide association studies of plasma proteome (<jats:italic>N<\/jats:italic>\u2009=\u20093301 healthy individuals) and MM (598 cases and 180,756 controls). Sensitivity analyses were performed for these identified causal proteins. Furthermore, we pursued the exploration of enriched biological pathways, prioritized the therapeutic proteins, and evaluated their druggability using the KEGG pathway analysis, MR-Bayesian model averaging analysis, and cross-reference with current databases, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 13 proteins causally associated with MM risk (false discovery rate corrected <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Six proteins were positively associated with the risk of MM, including nicotinamide phosphoribosyl transferase (NAMPT; OR [95% CI]: 1.35 [1.18, 1.55]), tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE1; 1.14 [1.06, 1.22]), neutrophil cytosol factor 2 (NCF2; 1.27 [1.12, 1.44]), carbonyl reductase 1, cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D), platelet-activating factor acetylhydrolase IB subunit beta (PAFAH1B2). Seven proteins were inversely associated with MM, which referred to suppressor of cytokine signaling 3 (SOCS3; 0.90 [0.86, 0.94]), Fc-gamma receptor III-B (FCGR3B; 0.75 [0.65,0.86]), glypican-1 (GPC1; 0.69 [0.58,0.83]), follistatin-related protein 1, protein tyrosine phosphatase non-receptor type 4 (PTPN4), granzyme B, complement C1q subcomponent subunit C (C1QC). Three of the causal proteins, SOCS3, FCGR3B, and NCF2, were enriched in the osteoclast differentiation pathway in KEGG enrichment analyses while GPC1 (marginal inclusion probability (MIP):0.993; model averaged causal effects (MACE):\u2009\u2212\u20090.349), NAMPT (MIP:0.433; MACE:\u2009\u2212\u20090.113), and NCF2 (MIP:0.324; MACE:0.066) ranked among the top three MM-associated proteins according to MR-BMA analyses. Furthermore, therapeutics targeting four proteins are currently under evaluation, five are druggable and four are future breakthrough points.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our analysis revealed a set of 13 novel proteins, including six risk and seven protective proteins, causally linked to MM risk. The discovery of these MM-associated proteins opens up the possibility for identifying novel therapeutic targets, further advancing the integration of genome and proteome data for drug development.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-023-03086-0","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T16:02:04Z","timestamp":1696003324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma"],"prefix":"10.1186","volume":"21","author":[{"given":"Qiangsheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"issue":"5","key":"3086_CR1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"17","key":"3086_CR2","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","volume":"118","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blad\u00e9 J, Mateos MV, Rosi\u00f1ol L, Boccadoro M, Cavo M, Lokhorst H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519\u201329.","journal-title":"Blood"},{"key":"3086_CR3","doi-asserted-by":"crossref","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","DOI":"10.1038\/s41375-020-0734-z"},{"issue":"6","key":"3086_CR4","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cam4.1463","volume":"7","author":"X-W Cai","year":"2018","unstructured":"Cai X-W, Yu W-W, Yu W, Zhang Q, Feng W, Liu M-N, Sun M-H, Xiang J-Q, Zhang Y-W, Fu X-L. Tissue-based quantitative proteomics to screen and identify the potential biomarkers for early recurrence\/metastasis of esophageal squamous cell carcinoma. Cancer Med. 2018;7(6):2504\u201317.","journal-title":"Cancer Med"},{"issue":"5","key":"3086_CR5","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1021\/acs.jproteome.1c00007","volume":"20","author":"Y Chen","year":"2021","unstructured":"Chen Y, Quan L, Jia C, Guo Y, Wang X, Zhang Y, Jin Y, Liu A. Proteomics-based approach reveals the involvement of SERPINB9 in recurrent and relapsed multiple myeloma. J Proteome Res. 2021;20(5):2673\u201386.","journal-title":"J Proteome Res"},{"issue":"1","key":"3086_CR6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","volume":"13","author":"YLD Ng","year":"2022","unstructured":"Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, M\u00fcller S, Popp O, Kull M, Haji M, et al. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022;13(1):1009.","journal-title":"Nat Commun"},{"issue":"7","key":"3086_CR7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658\u201365.","journal-title":"Genet Epidemiol"},{"issue":"16","key":"3086_CR8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.121.056663","volume":"145","author":"A Henry","year":"2022","unstructured":"Henry A, Gordillo-Mara\u00f1\u00f3n M, Finan C, Schmidt AF, Ferreira JP, Karra R, Sundstr\u00f6m J, Lind L, \u00c4rnl\u00f6v J, Zannad F, et al. Therapeutic targets for heart failure identified using proteomics and mendelian randomization. Circulation. 2022;145(16):1205\u201317.","journal-title":"Circulation"},{"issue":"8","key":"3086_CR9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41416-022-01923-2","volume":"127","author":"X Shu","year":"2022","unstructured":"Shu X, Zhou Q, Sun X, Flesaker M, Guo X, Long J, Robson ME, Shu X-O, Zheng W, Bernstein JL. Associations between circulating proteins and risk of breast cancer by intrinsic subtypes: a Mendelian randomisation analysis. Br J Cancer. 2022;127(8):1507\u201314.","journal-title":"Br J Cancer"},{"issue":"11","key":"3086_CR10","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1007\/s00432-021-03740-1","volume":"147","author":"Z Yang","year":"2021","unstructured":"Yang Z, Yu R, Deng W, Wang W. Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer. J Cancer Res Clin Oncol. 2021;147(11):3279\u201388.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"3086_CR11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2020.11.016","volume":"160","author":"DPC Considine","year":"2021","unstructured":"Considine DPC, Jia G, Shu X, Schildkraut JM, Pharoah PDP, Zheng W, Kar SP. Genetically predicted circulating protein biomarkers and ovarian cancer risk. Gynecol Oncol. 2021;160(2):506\u201313.","journal-title":"Gynecol Oncol"},{"issue":"7708","key":"3086_CR12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","volume":"558","author":"BB Sun","year":"2018","unstructured":"Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73\u20139.","journal-title":"Nature"},{"issue":"7944","key":"3086_CR13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipil\u00e4 TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508\u201318.","journal-title":"Nature"},{"issue":"8","key":"3086_CR14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/sim.3034","volume":"27","author":"DA Lawlor","year":"2008","unstructured":"Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133\u201363.","journal-title":"Stat Med"},{"key":"3086_CR15","doi-asserted-by":"crossref","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R, Karlsson A, Santos R, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9(383):eaag1166.","DOI":"10.1126\/scitranslmed.aag1166"},{"issue":"D1","key":"3086_CR16","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","volume":"47","author":"D Mendez","year":"2019","unstructured":"Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, F\u00e9lix E, Magari\u00f1os MP, Mosquera JF, Mutowo P, Nowotka M, et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 2019;47(D1):D930\u201340.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"3086_CR17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41588-020-0622-5","volume":"52","author":"SA Gagliano Taliun","year":"2020","unstructured":"Gagliano Taliun SA, VandeHaar P, Boughton AP, Welch RP, Taliun D, Schmidt EM, Zhou W, Nielsen JB, Willer CJ, Lee S, et al. Exploring and visualizing large-scale genetic associations by using PheWeb. Nat Genet. 2020;52(6):550\u20132.","journal-title":"Nat Genet"},{"issue":"6","key":"3086_CR18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41588-020-0621-6","volume":"52","author":"W Zhou","year":"2020","unstructured":"Zhou W, Zhao Z, Nielsen JB, Fritsche LG, LeFaive J, Gagliano Taliun SA, Bi W, Gabrielsen ME, Daly MJ, Neale BM, et al. Scalable generalized linear mixed model for region-based association tests in large biobanks and cohorts. Nat Genet. 2020;52(6):634\u20139.","journal-title":"Nat Genet"},{"issue":"3","key":"3086_CR19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","volume":"40","author":"S Burgess","year":"2011","unstructured":"Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755\u201364.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"3086_CR20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41588-018-0307-5","volume":"51","author":"M Liu","year":"2019","unstructured":"Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, Datta G, Davila-Velderrain J, McGuire D, Tian C, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51(2):237\u201344.","journal-title":"Nat Genet"},{"issue":"6","key":"3086_CR21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41366-018-0120-3","volume":"42","author":"YC Klimentidis","year":"2018","unstructured":"Klimentidis YC, Raichlen DA, Bea J, Garcia DO, Wineinger NE, Mandarino LJ, Alexander GE, Chen Z, Going SB. Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int J Obes (Lond). 2018;42(6):1161\u201376.","journal-title":"Int J Obes (Lond)"},{"issue":"20","key":"3086_CR22","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1093\/hmg\/ddy271","volume":"27","author":"L Yengo","year":"2018","unstructured":"Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, Frayling TM, Hirschhorn J, Yang J, Visscher PM, et al. Meta-analysis of genome-wide association studies for height and body mass index in \u223c700000 individuals of European ancestry. Hum Mol Genet. 2018;27(20):3641\u20139.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"3086_CR23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/EDE.0000000000001072","volume":"30","author":"RAJ Smit","year":"2019","unstructured":"Smit RAJ, Trompet S, Dekkers OM, Jukema JW, le Cessie S. Survival bias in Mendelian randomization studies: a threat to causal inference. Epidemiology. 2019;30(6):813\u20136.","journal-title":"Epidemiology"},{"issue":"10","key":"3086_CR24","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/ijc.34214","volume":"151","author":"Q Wang","year":"2022","unstructured":"Wang Q, Shi Q, Lu J, Wang Z, Hou J. Causal relationships between inflammatory factors and multiple myeloma: a bidirectional Mendelian randomization study. Int J Cancer. 2022;151(10):1750\u20139.","journal-title":"Int J Cancer"},{"key":"3086_CR25","doi-asserted-by":"crossref","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.","DOI":"10.7554\/eLife.34408"},{"issue":"5","key":"3086_CR26","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ije\/dyt179","volume":"42","author":"M-JA Brion","year":"2013","unstructured":"Brion M-JA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5):1497\u2013501.","journal-title":"Int J Epidemiol"},{"issue":"21","key":"3086_CR27","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","volume":"31","author":"MJ Machiela","year":"2015","unstructured":"Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31(21):3555\u20137.","journal-title":"Bioinformatics"},{"issue":"11","key":"3086_CR28","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/sim.7221","volume":"36","author":"J Bowden","year":"2017","unstructured":"Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36(11):1783\u2013802.","journal-title":"Stat Med"},{"issue":"2","key":"3086_CR29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512\u201325.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"3086_CR30","first-page":"1961","volume":"45","author":"J Bowden","year":"2016","unstructured":"Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol. 2016;45(6):1961\u201374.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"3086_CR31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, Smith GD, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304\u201314.","journal-title":"Genet Epidemiol"},{"issue":"1","key":"3086_CR32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41467-017-02317-2","volume":"9","author":"Z Zhu","year":"2018","unstructured":"Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, Robinson MR, McGrath JJ, Visscher PM, Wray NR, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun. 2018;9(1):224.","journal-title":"Nat Commun"},{"issue":"11","key":"3086_CR33","doi-asserted-by":"crossref","first-page":"e1007081","DOI":"10.1371\/journal.pgen.1007081","volume":"13","author":"G Hemani","year":"2017","unstructured":"Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081.","journal-title":"PLoS Genet"},{"issue":"1","key":"3086_CR34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41467-019-13870-3","volume":"11","author":"V Zuber","year":"2020","unstructured":"Zuber V, Colijn JM, Klaver C, Burgess S. Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomization. Nat Commun. 2020;11(1):29.","journal-title":"Nat Commun"},{"issue":"3","key":"3086_CR35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/ije\/dyaa216","volume":"50","author":"V Zuber","year":"2021","unstructured":"Zuber V, Gill D, Ala-Korpela M, Langenberg C, Butterworth A, Bottolo L, Burgess S. High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease. Int J Epidemiol. 2021;50(3):893\u2013901.","journal-title":"Int J Epidemiol"},{"key":"3086_CR36","doi-asserted-by":"crossref","unstructured":"Julian TH, Cooper-Knock J, MacGregor S, Guo H, Aslam T, Sanderson E, Black GCM, Sergouniotis PI. Phenome-wide Mendelian randomisation analysis identifies causal factors for age-related macular degeneration. Elife. 2023;12:e82546.","DOI":"10.7554\/eLife.82546"},{"issue":"6","key":"3086_CR37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/onc.2014.4","volume":"34","author":"G Kim","year":"2015","unstructured":"Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D\u2019Angelo RC, Korkaya S, et al. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene. 2015;34(6):671\u201380.","journal-title":"Oncogene"},{"issue":"1","key":"3086_CR38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-021-01377-9","volume":"20","author":"Z-K Liu","year":"2021","unstructured":"Liu Z-K, Li C, Zhang R-Y, Wei D, Shang Y-K, Yong Y-L, Kong L-M, Zheng N-S, Liu K, Lu M, et al. EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK\/STAT signaling. Mol Cancer. 2021;20(1):79.","journal-title":"Mol Cancer"},{"issue":"17","key":"3086_CR39","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/blood-2012-03-416776","volume":"120","author":"M Cea","year":"2012","unstructured":"Cea M, Cagnetta A, Fulciniti M, Tai Y-T, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1\/2) inhibition. Blood. 2012;120(17):3519\u201329.","journal-title":"Blood"},{"issue":"4","key":"3086_CR40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood-2009-11-252668","volume":"116","author":"RJ Rickles","year":"2010","unstructured":"Rickles RJ, Pierce LT, Giordano TP, Tam WF, McMillin DW, Delmore J, Laubach JP, Borisy AA, Richardson PG, Lee MS. Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood. 2010;116(4):593\u2013602.","journal-title":"Blood"},{"issue":"8","key":"3086_CR41","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41416-020-01237-1","volume":"124","author":"R Kumari","year":"2021","unstructured":"Kumari R, Majumder MM, Lievonen J, Silvennoinen R, Anttila P, Nupponen NN, Lehmann F, Heckman CA. Prognostic significance of esterase gene expression in multiple myeloma. Br J Cancer. 2021;124(8):1428\u201336.","journal-title":"Br J Cancer"},{"issue":"2","key":"3086_CR42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3324\/haematol.2012.065607","volume":"98","author":"P Liang","year":"2013","unstructured":"Liang P, Cheng SH, Cheng CK, Lau KM, Lin SY, Chow EYD, Chan NPH, Ip RKL, Wong RSM, Ng MHL. Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica. 2013;98(2):288\u201395.","journal-title":"Haematologica"},{"key":"3086_CR43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jconrel.2020.02.004","volume":"320","author":"Y Zhong","year":"2020","unstructured":"Zhong Y, Meng F, Zhang W, Li B, van Hest JCM, Zhong Z. CD44-targeted vesicles encapsulating granzyme B as artificial killer cells for potent inhibition of human multiple myeloma in mice. J Control Release. 2020;320:421\u201330.","journal-title":"J Control Release"},{"issue":"1","key":"3086_CR44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-018-0689-y","volume":"12","author":"S Raimondo","year":"2019","unstructured":"Raimondo S, Saieva L, Vicario E, Pucci M, Toscani D, Manno M, Raccosta S, Giuliani N, Alessandro R. Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis. J Hematol Oncol. 2019;12(1):2.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3086_CR45","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1038\/s41467-023-39769-8","volume":"14","author":"J Fu","year":"2023","unstructured":"Fu J, Li S, Ma H, Yang J, Pagnotti GM, Brown LM, Weiss SJ, Mapara MY, Lentzsch S. The checkpoint inhibitor PD-1H\/VISTA controls osteoclast-mediated multiple myeloma bone disease. Nat Commun. 2023;14(1):4271.","journal-title":"Nat Commun"},{"issue":"23","key":"3086_CR46","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood.2020006045","volume":"136","author":"M Westhrin","year":"2020","unstructured":"Westhrin M, Kovcic V, Zhang Z, Moen SH, Nedal TMV, Bondt A, Holst S, Misund K, Buene G, Sundan A, et al. Monoclonal immunoglobulins promote bone loss in multiple myeloma. Blood. 2020;136(23):2656\u201366.","journal-title":"Blood"},{"issue":"3","key":"3086_CR47","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos E, Zamagni E, Lentzsch S, Drake MT, Garc\u00eda-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e119\u201330.","journal-title":"Lancet Oncol"},{"key":"3086_CR48","doi-asserted-by":"crossref","first-page":"100999","DOI":"10.1016\/j.blre.2022.100999","volume":"57","author":"M Hussain","year":"2023","unstructured":"Hussain M, Khan F, Al Hadidi S. The use of bone-modifying agents in multiple myeloma. Blood Rev. 2023;57:100999.","journal-title":"Blood Rev"},{"issue":"17","key":"3086_CR49","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1007\/s00018-016-2234-x","volume":"73","author":"R Mahony","year":"2016","unstructured":"Mahony R, Ahmed S, Diskin C, Stevenson NJ. SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use? Cell Mol Life Sci. 2016;73(17):3323\u201336.","journal-title":"Cell Mol Life Sci"},{"issue":"25","key":"3086_CR50","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.2174\/0929867328666201207202012","volume":"28","author":"F Shao","year":"2021","unstructured":"Shao F, Pang X, Baeg GH. Targeting the JAK\/STAT signaling pathway for breast cancer. Curr Med Chem. 2021;28(25):5137\u201351.","journal-title":"Curr Med Chem"},{"issue":"9","key":"3086_CR51","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1210\/en.2010-0244","volume":"151","author":"S Shanmugarajan","year":"2010","unstructured":"Shanmugarajan S, Beeson CC, Reddy SV. Osteoclast inhibitory peptide-1 binding to the Fc gammaRIIB inhibits osteoclast differentiation. Endocrinology. 2010;151(9):4389\u201399.","journal-title":"Endocrinology"},{"issue":"3","key":"3086_CR52","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood-2004-09-3662","volume":"106","author":"NK Lee","year":"2005","unstructured":"Lee NK, Choi YG, Baik JY, Han SY, Jeong D-W, Bae YS, Kim N, Lee SY. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood. 2005;106(3):852\u20139.","journal-title":"Blood"},{"key":"3086_CR53","doi-asserted-by":"crossref","unstructured":"Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S. NAMPT\/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013;41(6):547\u2013557.e2.","DOI":"10.1016\/j.exphem.2013.02.008"},{"issue":"7","key":"3086_CR54","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41375-019-0692-5","volume":"34","author":"L Korotchkina","year":"2020","unstructured":"Korotchkina L, Kazyulkin D, Komarov PG, Polinsky A, Andrianova EL, Joshi S, Gupta M, Vujcic S, Kononov E, Toshkov I, et al. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia. 2020;34(7):1828\u201339.","journal-title":"Leukemia"},{"issue":"20","key":"3086_CR55","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1038\/s41388-018-0162-y","volume":"37","author":"J-X Zhang","year":"2018","unstructured":"Zhang J-X, Chen Z-H, Chen D-L, Tian X-P, Wang C-Y, Zhou Z-W, Gao Y, Xu Y, Chen C, Zheng Z-S, et al. LINC01410-miR-532-NCF2-NF-kB feedback loop promotes gastric cancer angiogenesis and metastasis. Oncogene. 2018;37(20):2660\u201375.","journal-title":"Oncogene"},{"issue":"11","key":"3086_CR56","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.3324\/haematol.2021.279889","volume":"107","author":"R Paolillo","year":"2022","unstructured":"Paolillo R, Boulanger M, G\u00e2tel P, Gabellier L, De Toledo M, Temp\u00e9 D, Hallal R, Akl D, Moreaux J, Baik H, et al. The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias. Haematologica. 2022;107(11):2562\u201375.","journal-title":"Haematologica"},{"issue":"1","key":"3086_CR57","doi-asserted-by":"crossref","first-page":"11478","DOI":"10.1038\/s41598-019-47874-2","volume":"9","author":"ND Quach","year":"2019","unstructured":"Quach ND, Kaur SP, Eggert MW, Ingram L, Ghosh D, Sheth S, Nagy T, Dawson MR, Arnold RD, Cummings BS. Paradoxical role of glypican-1 in prostate cancer cell and tumor growth. Sci Rep. 2019;9(1):11478.","journal-title":"Sci Rep"},{"issue":"1","key":"3086_CR58","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.1038\/s41598-021-88519-7","volume":"11","author":"SP Kaur","year":"2021","unstructured":"Kaur SP, Verma A, Lee HK, Barnett LM, Somanath PR, Cummings BS. Inhibition of glypican-1 expression induces an activated fibroblast phenotype in a human bone marrow-derived stromal cell-line. Sci Rep. 2021;11(1):9262.","journal-title":"Sci Rep"},{"issue":"2","key":"3086_CR59","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI94674","volume":"128","author":"S La Porta","year":"2018","unstructured":"La Porta S, Roth L, Singhal M, Mogler C, Spegg C, Schieb B, Qu X, Adams RH, Baldwin HS, Savant S, et al. Endothelial Tie1-mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis. J Clin Invest. 2018;128(2):834\u201345.","journal-title":"J Clin Invest"},{"issue":"2","key":"3086_CR60","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1172\/JCI68897","volume":"124","author":"G D'Amico","year":"2014","unstructured":"D\u2019Amico G, Korhonen EA, Anisimov A, Zarkada G, Holopainen T, H\u00e4gerling R, Kiefer F, Eklund L, Sormunen R, Elamaa H, et al. Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. J Clin Invest. 2014;124(2):824\u201334.","journal-title":"J Clin Invest"},{"issue":"4","key":"3086_CR61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/cns.12834","volume":"24","author":"A Cardinale","year":"2018","unstructured":"Cardinale A, Fusco FR. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington\u2019s disease. CNS Neurosci Ther. 2018;24(4):319\u201328.","journal-title":"CNS Neurosci Ther"},{"issue":"8","key":"3086_CR62","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1158\/1078-0432.CCR-17-2776","volume":"24","author":"RR Mishra","year":"2018","unstructured":"Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U, Ersan PG, Tokat \u00dcM, Ey\u00fcpo\u011flu E, Saatci \u00d6, et al. Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer. Clin Cancer Res. 2018;24(8):1987\u20132001.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3086_CR63","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-08-3901","volume":"69","author":"EP Rahrmann","year":"2009","unstructured":"Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, et al. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res. 2009;69(10):4388\u201397.","journal-title":"Cancer Res"},{"key":"3086_CR64","doi-asserted-by":"crossref","first-page":"215749","DOI":"10.1016\/j.canlet.2022.215749","volume":"541","author":"H Ren","year":"2022","unstructured":"Ren H, Chen Y, Ao Z, Cheng Q, Yang X, Tao H, Zhao L, Shen A, Li P, Fu Q. PDE4D binds and interacts with YAP to cooperatively promote HCC progression. Cancer Lett. 2022;541:215749.","journal-title":"Cancer Lett"},{"key":"3086_CR65","doi-asserted-by":"crossref","unstructured":"Gupta DG, Varma N, Kumar A, Naseem S, Sachdeva MUS, Sreedharanunni S, Binota J, Bose P, Khadwal A, Malhotra P, et al. Genomic and proteomic characterization of Philadelphia-like B-lineage acute lymphoblastic leukemia: a report of Indian patients. Cancer. 2023;129(8):1217\u201326.","DOI":"10.1002\/cncr.34665"},{"issue":"1","key":"3086_CR66","doi-asserted-by":"crossref","first-page":"9830","DOI":"10.1038\/s41598-017-10366-2","volume":"7","author":"J Chiou","year":"2017","unstructured":"Chiou J, Su C-Y, Jan Y-H, Yang C-J, Huang M-S, Yu Y-L, Hsiao M. Decrease of FSTL1-BMP4-Smad signaling predicts poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma. Sci Rep. 2017;7(1):9830.","journal-title":"Sci Rep"},{"key":"3086_CR67","doi-asserted-by":"crossref","first-page":"940306","DOI":"10.3389\/fgene.2022.940306","volume":"13","author":"H Yang","year":"2022","unstructured":"Yang H, Che D, Gu Y, Cao D. Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma. Front Genet. 2022;13:940306.","journal-title":"Front Genet"},{"issue":"8","key":"3086_CR68","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s12276-022-00837-6","volume":"54","author":"J Gan","year":"2022","unstructured":"Gan J, Liu S, Zhang Y, He L, Bai L, Liao R, Zhao J, Guo M, Jiang W, Li J, et al. MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4\/STAT3 axis. Exp Mol Med. 2022;54(8):1290\u2013305.","journal-title":"Exp Mol Med"},{"issue":"3","key":"3086_CR69","doi-asserted-by":"crossref","first-page":"e1010042","DOI":"10.1371\/journal.pgen.1010042","volume":"18","author":"AB Palmos","year":"2022","unstructured":"Palmos AB, Millischer V, Menon DK, Nicholson TR, Taams LS, Michael B, Sunderland G, Griffiths MJ, H\u00fcbel C, Breen G. Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19. PLoS Genet. 2022;18(3):e1010042.","journal-title":"PLoS Genet"},{"key":"3086_CR70","doi-asserted-by":"crossref","unstructured":"Joshi H, Lin S, Fei KZ, Renteria AS, Jacobs H, Mazumdar M, Jagannath S, Bickell NA. Multiple myeloma, race, insurance and treatment. Cancer Epidemiol. 2021;73:101974.","DOI":"10.1016\/j.canep.2021.101974"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03086-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-03086-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03086-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:20:20Z","timestamp":1700493620000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-03086-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3086"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-03086-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]},"assertion":[{"value":"12 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies included in cited genome-wide association studies had approved by a relevant review board. All participants had provided the inform consent. The GWAS of proteome was approved by National Research Ethics Service (11\/EE\/0538). The GWASs of multiple myeloma in FinnGen consortium and UK Biobank were approved by the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS\/990\/2017) and North West Multi-center Research Ethics Committee (11\/NW\/0382), respectively.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}